Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with…

Overview of attention for article published in Journal of Clinical Oncology, May 2025

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

news: 2 news outlets

Readers on

mendeley: 4 Mendeley

So far, Altmetric has seen 4 news stories from 2 outlets.

Unpacking the EPCORE NHL-1 Trial and Epcoritamab’s Promise in R/R LBCL

Cancer Network, 03 Jul 2025

The EPCORE NHL-1 trial showed a 41% complete response rate with epcoritamab for patients with relapsed/refractory LBCL.

Epcoritamab Elicited Sustained PFS and OS at 3 Years in R/R LBCL

Cancer Network, 10 Jun 2025

Epcoritamab monotherapy led to long-term disease-free remissions in patients with relapsed/refractory large B-cell lymphoma who…

Epcoritamab Maintains Responses at 3 Years in Relapsed/Refractory LBCL

OncLive, 05 Jun 2025

Epcoritamab in Relapsed/Refractory LBCL | Image credit: © Bipul Kumar - stock.adobe.com Epcoritamab-bysp (Epkinly) led to…

Epcoritamab Demonstrates Complete Responses at 2 Years in R/R LBCL

Cancer Network, 04 Jun 2025

At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Julie M.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity.